SG10201608871XA - Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof - Google Patents

Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof

Info

Publication number
SG10201608871XA
SG10201608871XA SG10201608871XA SG10201608871XA SG10201608871XA SG 10201608871X A SG10201608871X A SG 10201608871XA SG 10201608871X A SG10201608871X A SG 10201608871XA SG 10201608871X A SG10201608871X A SG 10201608871XA SG 10201608871X A SG10201608871X A SG 10201608871XA
Authority
SG
Singapore
Prior art keywords
methods
cross
reactive antibodies
antibodies
reactive
Prior art date
Application number
SG10201608871XA
Inventor
Krzysztof Masternak
Olivier Leger
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41265089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201608871X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novimmune Sa filed Critical Novimmune Sa
Publication of SG10201608871XA publication Critical patent/SG10201608871XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG10201608871XA 2008-05-05 2009-05-05 Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof SG10201608871XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12646508P 2008-05-05 2008-05-05
US9836908P 2008-09-19 2008-09-19

Publications (1)

Publication Number Publication Date
SG10201608871XA true SG10201608871XA (en) 2016-12-29

Family

ID=41265089

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201608871XA SG10201608871XA (en) 2008-05-05 2009-05-05 Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
SG2013034020A SG190626A1 (en) 2008-05-05 2009-05-05 Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013034020A SG190626A1 (en) 2008-05-05 2009-05-05 Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof

Country Status (19)

Country Link
US (4) US20090317400A1 (en)
EP (1) EP2288382B1 (en)
JP (4) JP2011519911A (en)
KR (5) KR20170023209A (en)
CN (2) CN102083858B (en)
AU (1) AU2009245440C1 (en)
BR (1) BRPI0908312A2 (en)
CA (1) CA2721713C (en)
CO (1) CO6351800A2 (en)
EC (1) ECSP10010653A (en)
HK (1) HK1210484A1 (en)
IL (2) IL208808A (en)
MA (1) MA32365B1 (en)
MX (2) MX355256B (en)
NZ (3) NZ623706A (en)
RU (2) RU2474588C2 (en)
SG (2) SG10201608871XA (en)
WO (1) WO2009136286A2 (en)
ZA (1) ZA201007452B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2784084T2 (en) 2003-07-08 2024-02-29 Novartis Pharma Ag Antagonist antibodies to IL-17A/F heterologous polypeptides
EP2190878A1 (en) * 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer
KR20170023209A (en) 2008-05-05 2017-03-02 노비뮨 에스 에이 Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
CN104974250A (en) * 2009-05-05 2015-10-14 诺维莫尼公司 Anti-il-17f antibodies and methods of use thereof
EP2477647B1 (en) 2009-09-14 2016-01-13 The Regents of the University of Colorado Modulation of yeast-based immunotherapy products and responses
DK2519542T3 (en) * 2009-12-28 2019-01-14 Onco Therapy Science Inc ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
WO2011100567A1 (en) * 2010-02-11 2011-08-18 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic inhibition of granulocyte function in demyelinating disease
US20110301053A1 (en) * 2010-05-06 2011-12-08 Singulex, Inc. Methods for Diagnosing, Staging, Predicting Risk for Developing and Identifying Treatment Responders for Rheumatoid Arthritis
WO2011144749A1 (en) 2010-05-20 2011-11-24 Ablynx Nv Biological materials related to her3
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
RS56298B1 (en) * 2011-01-14 2017-12-29 Ucb Biopharma Sprl Antibody binding il-17a and il-17f
ES2649964T3 (en) 2011-02-08 2018-01-16 Merck Patent Gmbh Aminostatin derivatives for the treatment of osteoarthritis
UA117218C2 (en) * 2011-05-05 2018-07-10 Мерк Патент Гмбх Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
CA2861793C (en) * 2011-12-28 2023-08-01 Immunoqure Ag Method of providing monoclonal auto-antibodies with desired specificity
CN104884473B (en) 2012-05-22 2019-12-03 百时美施贵宝公司 IL-17A/F IL-23 bispecific antibody and its application
US9676847B2 (en) 2012-06-25 2017-06-13 Orega Biotech IL-17 antagonist antibodies
EP3683232A1 (en) 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
KR102332302B1 (en) 2013-09-13 2021-12-01 제넨테크, 인크. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
HUE052184T2 (en) * 2013-11-18 2021-12-28 Shanghai hengrui pharmaceutical co ltd Il-17a binding agent and uses thereof
KR20160124165A (en) * 2014-02-21 2016-10-26 제넨테크, 인크. Anti-il-13/il-17 bispecific antibodies and uses thereof
EP3212665A2 (en) * 2014-10-31 2017-09-06 F. Hoffmann-La Roche AG Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same
KR102544705B1 (en) 2014-11-05 2023-06-15 제넨테크, 인크. Methods of producing two chain proteins in bacteria
KR20170075793A (en) * 2014-11-05 2017-07-03 제넨테크, 인크. Methods of producing two chain proteins in bacteria
ES2835823T3 (en) 2014-11-20 2021-06-23 Hoffmann La Roche Combination of T-cell activating bispecific antigen-binding molecules for CD3 and folate receptor 1 (FolR1) and PD-1 axis-binding antagonists
KR20170089013A (en) * 2014-12-15 2017-08-02 모르포시스 아게 Antibodies for il-17c
JP2018506275A (en) 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド Gene expression markers and treatment of multiple sclerosis
MX2017011486A (en) * 2015-03-16 2018-06-15 Genentech Inc Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases.
CN108290927B (en) * 2015-07-15 2022-06-24 加州理工学院 IL-17F-specific capture agents, compositions, and methods of use and manufacture
JP7091238B2 (en) * 2015-08-20 2022-06-27 ジェネンテック， インコーポレイテッド Purification of FKPA and its use for the production of recombinant polypeptides
MX2018005031A (en) 2015-10-27 2018-06-13 Ucb Biopharma Sprl Methods of treatment using anti-il-17a/f antibodies.
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
RU2680011C2 (en) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Trispecific il-17a, il-17f and other proinflammatory molecules antibodies
CN107488227A (en) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 Anti-human IL-17 A monoclonal antibodies, its preparation method and application
WO2018050028A1 (en) 2016-09-14 2018-03-22 北京韩美药品有限公司 Antibody specifically binding to il-17a and functional fragment thereof
AR110873A1 (en) 2017-02-10 2019-05-08 Genentech Inc ANTIBODIES AGAINST TRIPTASE, COMPOSITIONS OF THESE AND USES OF THESE
JP6876156B2 (en) * 2017-03-10 2021-05-26 スージョウ カノヴァ バイオファーマシューティカル カンパニーリミテッドＳｕｚｈｏｕ Ｋａｎｏｖａ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Monoclonal antibodies that react with IL-17A and IL-17F, and their use
KR20200083996A (en) 2017-11-02 2020-07-09 노파르티스 아게 How to treat tendinosis using interleukin-17 (IL-17)
WO2020121282A1 (en) * 2018-12-13 2020-06-18 Argenx Bvba Antibodies to human complement factor c2b and methods of use
CN113710701A (en) * 2019-02-02 2021-11-26 华辉安健（北京）生物科技有限公司 anti-FGF 19 antibodies
IL297689A (en) * 2020-04-30 2022-12-01 Janssen Pharmaceutica Nv Methods of identifying modulators of the il-17 pathway
IL310700A (en) * 2021-08-09 2024-04-01 Merck Patent Gmbh Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
WO2023223211A1 (en) 2022-05-16 2023-11-23 Novartis Ag Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
WO2023223263A1 (en) 2022-05-18 2023-11-23 Novartis Ag Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
EP4393948A1 (en) * 2022-12-28 2024-07-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic vhh antibodies cross-neutralizing the il-17a and il-17f homodimers as well as the il-17af heterodimer

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738681A (en) * 1985-07-10 1988-04-19 Harrington Arthritis Research Center Femoral-joint prosthetic device
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
SE500903C2 (en) 1989-12-20 1994-09-26 Atlas Copco Constr & Mining Rock drilling rig
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5364839A (en) 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5273033A (en) * 1991-09-19 1993-12-28 Murray Electronics Associates Limited Partnership Electrical stimulation for treatment of osteoarthritis
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
WO1993023556A1 (en) * 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
GB9214857D0 (en) 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5444047A (en) * 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
WO2000073452A2 (en) 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5869286A (en) 1995-03-23 1999-02-09 Immunex Corporation Receptor that binds IL-17
US5573762A (en) * 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
US6902735B1 (en) 1995-07-19 2005-06-07 Genetics Institute, Llc Antibodies to human IL-17F and other CTLA-8-related proteins
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
CA2227220A1 (en) 1995-07-19 1997-02-06 Genetics Institute, Inc. Human ctla-8 and uses of ctla-8-related proteins
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
AU1407997A (en) 1995-12-01 1997-06-19 Beth Israel Hospital Il-12 p40 subunit fusion polypeptides and uses thereof
KR19990077146A (en) 1996-01-11 1999-10-25 길리스 스티브 Compositions and methods for treating and diagnosing breast cancer
EP0959897B1 (en) * 1996-11-27 2009-04-22 Immunex Corporation Method of regulating nitric oxide production
US6054559A (en) * 1997-01-28 2000-04-25 Smithkline Beecham Corporation Interleukin-1 receptor antagonist beta (IL-1raβ)
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
WO2000053752A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US6569645B2 (en) * 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20020177188A1 (en) * 1998-05-15 2002-11-28 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
CN1258315A (en) 1997-04-25 2000-06-28 津莫吉尼蒂克斯公司 Mammalian cytokine-like factor-7
EP1012260A4 (en) 1997-07-16 2001-05-09 Human Genome Sciences Inc Interleukin-20
PE20000183A1 (en) 1997-07-25 2000-03-11 Schering Corp MAMMAL CYTOKINES AND RELATED REAGENTS
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6635443B1 (en) 1997-09-17 2003-10-21 Human Genome Sciences, Inc. Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
US6562578B1 (en) * 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
WO1999032632A1 (en) 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
KR100558288B1 (en) 1997-12-19 2006-03-10 와이어쓰 Transgenic animal model for degenerative diseases of cartilage
WO1999035267A1 (en) 1998-01-09 1999-07-15 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
ES2312205T3 (en) 1998-03-10 2009-02-16 Genentech, Inc. NEW POLYPEPTIDE AND NUCLEIC ACIDS THAT CODE IT.
EP1386931B1 (en) 1998-03-25 2006-05-10 Genentech, Inc. Human neurotrimin homologue
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO1999054357A1 (en) * 1998-04-14 1999-10-28 Chugai Research Institute For Molecular Medicine, Inc. Novel cytokine-like protein
US7771719B1 (en) * 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
DE69936382T3 (en) * 1998-05-15 2011-07-07 Genentech, Inc., Calif. THERAPEUTIC USES OF IL-17 HOMOLOGOUS POLYPEPTIDE
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
EP1082433A4 (en) * 1998-05-29 2003-01-02 Human Genome Sciences Inc Interleukins-21 and 22
EP1443055A3 (en) 1998-05-29 2005-06-08 Human Genome Sciences, Inc. Interleukins-21 and 22
IL141869A0 (en) 1998-09-17 2002-03-10 Zymogenetics Inc Mammalian transforming growth factor beta-9 (ztgfss9)
WO2000020593A1 (en) 1998-10-02 2000-04-13 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
JP2000186046A (en) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd Therapeutic agent for and diagnosis of chronic rheumatism and
WO2000042187A1 (en) 1999-01-11 2000-07-20 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
PT1141297E (en) 1999-01-11 2010-01-06 Schering Corp Interleukin-17 related mammalian cytokines. polynucleotides encoding them . uses
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
TR200102715T2 (en) 1999-03-25 2002-09-23 Knoll Gmbh Human antibodies that bind human IL-12 and methods for producing them.
AU3632600A (en) 1999-05-14 2000-12-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
US20030082734A1 (en) * 1999-06-01 2003-05-01 Dowling Lynette M. Mammalian receptor proteins; related reagents and methods
AU6069800A (en) 1999-07-07 2001-01-30 Zymogenetics Inc. Human cytokine receptor
US20030199041A1 (en) * 1999-07-07 2003-10-23 Presnell Scott R. Interleukin-17 receptor homologue
WO2001012659A2 (en) 1999-08-18 2001-02-22 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Human dna sequences
EP1208202A2 (en) 1999-09-01 2002-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2383800A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences Inc. 52 human secreted proteins
AU7445900A (en) * 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
EP1234036A2 (en) 1999-11-30 2002-08-28 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6380362B1 (en) 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
ATE444361T1 (en) 1999-12-23 2009-10-15 Genentech Inc IL-17 AND IL-17R HOMOLOGUE POLYPEPTIDES AND THERAPEUTIC USES
US20040043397A1 (en) * 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP1254221A2 (en) 2000-01-06 2002-11-06 Protegene Inc. HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
EP1285084A1 (en) 2000-01-25 2003-02-26 Hyseq, Inc. Novel nucleic acids and polypeptides
US7094886B2 (en) 2000-02-04 2006-08-22 Board Of Trustees Of The University Of Arkansas Evi27 gene sequences and protein encoded thereby
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
TWI322154B (en) 2000-03-16 2010-03-21 Amgen Inc Il-17 receptor like molecules and uses thereof
JP2003526370A (en) 2000-03-16 2003-09-09 アムジェン インコーポレーテッド IL-17 receptor-like molecules and uses thereof
US7094566B2 (en) * 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
JP2003528149A (en) * 2000-03-24 2003-09-24 ジェネンテック・インコーポレーテッド Use of insulin for the treatment of cartilage disorders
US6479636B1 (en) 2000-04-11 2002-11-12 Honiron Corporation (A Louisiana Corporation) Sugarcane fractioning system
DE60136921D1 (en) 2000-04-18 2009-01-22 Schering Corp Medical use of IL-174 agonists and antagonists
AU6135101A (en) * 2000-05-10 2001-11-20 Schering Corp Mammalian receptor proteins; related reagents and methods
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
CA2410083A1 (en) 2000-05-24 2001-11-29 Schering Corporation Mammalian receptor proteins; related reagents and methods
US20030096969A1 (en) * 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004504064A (en) 2000-06-22 2004-02-12 アムジエン・インコーポレーテツド IL-17 molecule and its use
CA2412211A1 (en) 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2416456A1 (en) 2000-07-20 2002-01-31 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004516013A (en) 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド Compositions and methods for diagnosing and treating disorders associated with angiogenesis
EP1332211A2 (en) * 2000-07-26 2003-08-06 ZymoGenetics, Inc. Human cytokine receptor
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
JP2002139499A (en) * 2000-08-23 2002-05-17 Sanyo Electric Co Ltd Chemical substance sensor and method for detecting chemical substance
JP2002076897A (en) * 2000-08-29 2002-03-15 Toshiba Corp Digital/analog converter
DE60125563T2 (en) 2000-10-13 2007-10-04 Eli Lilly And Co., Indianapolis METHOD FOR USE OF A HUMAN IL-17 RELATED POLYPEPTIDE FOR THE TREATMENT OF DISEASES
GB2372464B (en) 2001-02-22 2003-05-14 Vivascience Ltd Method of isolating a charged compound
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
AU2002324625B2 (en) * 2001-08-07 2008-05-08 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
WO2003032810A2 (en) 2001-10-15 2003-04-24 Genentech, Inc. Treatment and diagnosis of insulin resistant states
CA2421692A1 (en) * 2002-03-12 2003-09-12 David J. Pisani Disposable bedding with absorbent region
DK1576011T3 (en) * 2002-10-30 2009-11-30 Genentech Inc Inhibition of IL-17 production
AU2004219625B9 (en) * 2003-03-10 2010-12-23 Merck Sharp & Dohme Corp. Uses of IL-23 agonists and antagonists; related reagents
DE602004030341D1 (en) 2003-06-23 2011-01-13 Genetics Inst Llc ANTIBODIES TO INTERLEUKIN-22 AND USES THEREOF
SI2784084T2 (en) 2003-07-08 2024-02-29 Novartis Pharma Ag Antagonist antibodies to IL-17A/F heterologous polypeptides
TW200528106A (en) * 2003-11-10 2005-09-01 Synta Pharmaceuticals Corp Pyridine compounds
EP1687002A4 (en) * 2003-11-10 2008-07-23 Synta Pharmaceuticals Corp Fused heterocyclic compounds
WO2005046604A2 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Heteroaryl-hydrazone compounds
AU2004292393C1 (en) 2003-11-21 2011-08-04 Ucb Pharma S.A. Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
US8263080B2 (en) * 2004-02-17 2012-09-11 Schering Corporation Use of agonists and antagonists of IL-23 in the treatment of viral infection
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
JP2007535930A (en) 2004-05-03 2007-12-13 シェーリング　コーポレイション Use of IL-17 expression to predict skin inflammation; treatment methods
CA2569867A1 (en) * 2004-06-10 2005-12-29 Zymogenetics, Inc. Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation
US7629691B2 (en) 2004-06-16 2009-12-08 Honeywell International Inc. Conductor geometry for electronic circuits fabricated on flexible substrates
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (en) * 2004-09-24 2007-01-17 Centocor Inc PROTEINS DERIVED FROM IL-23P40 SPECIFIC IMMUNOGLOBULIN, COMPOSITIONS, EPITHOPES, METHODS AND USES
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
AU2005313971B2 (en) 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
JP2008532936A (en) * 2005-02-14 2008-08-21 ワイス Interleukin-17F antibody and other IL-17F signaling antagonists and uses thereof
WO2006132788A2 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
US20080199460A1 (en) 2005-09-01 2008-08-21 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
US20070249533A1 (en) 2005-09-28 2007-10-25 Levin Steven D Il-17a and il-17f antagonists and methods of using the same
UA96139C2 (en) 2005-11-08 2011-10-10 Дженентек, Інк. Anti-neuropilin-1 (nrp1) antibody
RS57255B1 (en) 2005-12-13 2018-08-31 Lilly Co Eli Anti-il-17 antibodies
US7981937B2 (en) * 2006-01-11 2011-07-19 Aurora Specialty Chemistries Corp. Aurora Stable dispersion of DBNPA in viscosified brine
BRPI0706788A2 (en) 2006-01-31 2011-04-05 Novartis Ag il-17 antagonist antibodies
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
US7790163B2 (en) * 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
EP2377887A1 (en) 2006-03-10 2011-10-19 Zymogenetics Inc Antibodies that bind both IL-17A and IL-17F and methods of using the same
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
JP2010522564A (en) 2007-03-26 2010-07-08 ザイモジェネティクス， インコーポレイテッド Soluble IL-17RA / RC fusion protein and related methods
CA2682889C (en) * 2007-04-27 2016-04-05 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
WO2008134659A2 (en) 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
US20100239590A1 (en) 2007-06-20 2010-09-23 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
EP2182943B1 (en) 2007-07-23 2016-10-26 Janssen Biotech, Inc. Methods and compositions for treating fibrosis related disorders using il-17 antagonists
WO2009026412A1 (en) 2007-08-21 2009-02-26 Children's Medical Center Corporation Treatment of airway hyperreactivity
GB0807413D0 (en) * 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
KR20170023209A (en) 2008-05-05 2017-03-02 노비뮨 에스 에이 Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
EP2413967A1 (en) 2009-04-01 2012-02-08 F. Hoffmann-La Roche AG Treatment of insulin-resistant disorders
CN104974250A (en) 2009-05-05 2015-10-14 诺维莫尼公司 Anti-il-17f antibodies and methods of use thereof

Also Published As

Publication number Publication date
JP2017048191A (en) 2017-03-09
ECSP10010653A (en) 2011-02-28
EP2288382A2 (en) 2011-03-02
RU2474588C2 (en) 2013-02-10
ZA201007452B (en) 2012-01-25
CN102083858B (en) 2015-01-14
US20120269820A1 (en) 2012-10-25
KR20160028505A (en) 2016-03-11
WO2009136286A2 (en) 2009-11-12
KR20110025649A (en) 2011-03-10
US20120141492A1 (en) 2012-06-07
US20130195872A1 (en) 2013-08-01
NZ623706A (en) 2015-12-24
US8715669B2 (en) 2014-05-06
US9650437B2 (en) 2017-05-16
HK1210484A1 (en) 2016-04-22
CN102083858A (en) 2011-06-01
JP2014001217A (en) 2014-01-09
NZ600584A (en) 2014-05-30
RU2010149746A (en) 2012-06-20
AU2009245440A1 (en) 2009-11-12
AU2009245440C1 (en) 2013-03-14
IL208808A (en) 2015-04-30
JP2011519911A (en) 2011-07-14
EP2288382B1 (en) 2018-08-29
CA2721713A1 (en) 2009-11-12
BRPI0908312A2 (en) 2015-08-18
CO6351800A2 (en) 2011-12-20
US8771697B2 (en) 2014-07-08
RU2012151478A (en) 2014-06-10
MX355256B (en) 2018-04-11
KR20130138354A (en) 2013-12-18
US20090317400A1 (en) 2009-12-24
CA2721713C (en) 2019-07-09
WO2009136286A3 (en) 2010-06-10
IL238051A0 (en) 2015-05-31
AU2009245440B2 (en) 2012-08-02
KR101711798B1 (en) 2017-03-02
KR101508086B1 (en) 2015-04-07
SG190626A1 (en) 2013-06-28
IL208808A0 (en) 2011-01-31
WO2009136286A9 (en) 2010-04-22
JP2015166355A (en) 2015-09-24
JP5898653B2 (en) 2016-04-06
CN104628855A (en) 2015-05-20
KR20150002874A (en) 2015-01-07
MA32365B1 (en) 2011-06-01
MX2010012090A (en) 2011-04-11
JP6507133B2 (en) 2019-04-24
KR20170023209A (en) 2017-03-02
NZ588674A (en) 2013-02-22

Similar Documents

Publication Publication Date Title
IL238051A0 (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
HK1215038A1 (en) Anti-il-17f antibodies and methods of use thereof il-17f
HK1256622A1 (en) Antibodies to il-6 and use thereof
IL248723B (en) Bcr-complex-specific antibodies and methods of using same
HRP20151096T1 (en) Epitopes of il-17a and il-17f and antibodies specific thereto
HK1223114A1 (en) Anti-factor xi monoclonal antibodies and methods of use thereof xi
HUE042940T2 (en) Anti-fxi antibodies and methods of use
IL224752A (en) Method of using interleukin il-1α antibodies
IL193444A0 (en) Antibodies that bind both il-17a and il-17f and methods of using the same
EP2212432A4 (en) Fully human anti-vegf antibodies and methods of using
IL201281A0 (en) Antibodies that bind both il - 17a and il-17f and methods of using the same
EP2427479A4 (en) Antibodies and methods of use thereof
IL211623A0 (en) Anti-notch2 antibodies and methods of use
EP2297202A4 (en) Anti-il-6/il-6r antibodies and methods of use thereof
IL210942A0 (en) Cross-reactive and bispecific anti-il 17a/f antibodies
EP2185719A4 (en) Anti-rantes antibodies and methods of use thereof
EP2322610A4 (en) Anti-human clcp1 antibody and use thereof